DV
Dividend Vision

ZLAB — Zai Lab Limited

Zai Lab Limited (ZLAB)

Total return is -7.3% over the past 8.9 years, 262.8 points behind SPY at 255.5%. Its deepest 1-year drawdown was 54.4%.

This is a single-stock equity holding in Zai Lab Limited, a biopharmaceutical company focused on developing and commercializing medicines for oncology, autoimmune, and infectious disease indications. The holding does not currently pay dividends, has no listed expense ratio, and operates as a direct equity investment rather than a diversified fund. This security appeals primarily to growth-oriented investors seeking exposure to the Chinese biotech sector rather than income-focused investors.

ZLAB key facts

Asset type
Stock
Asset class
Equity
Inception date
09/20/2017
Distribution frequency
None
Last close
$25.90
Market cap
$2,907,695,104
Average volume
1234000.0
Beta
0.781
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.69